Irbesartan Eg

Irbesartan, the active ingredient in Irbesartan Eg, is a Angiotensin II receptor blocker (ARB) presented as an oral dosage form for oral use. It is employed to lower blood pressure and protect kidney function in patients with hypertension, diabetic nephropathy, or heart failure.

GNH USA supplies Irbesartan Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan acts on the renin‑angiotensin‑aldosterone system to control blood pressure and reduce organ damage.

- Hypertension: lowers systolic and diastolic pressure, reducing cardiovascular risk. - Diabetic nephropathy: slows progression of kidney disease in patients with type 2 diabetes. - Heart failure: improves symptoms and decreases hospitalisation by reducing afterload.

Irbesartan is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness: especially after the first dose. - Headache: mild to moderate intensity. - Fatigue: feeling unusually tired. - Nasal congestion: stuffy or runny nose. - Diarrhoea: loose stools. - Elevated serum creatinine: mild increase in kidney markers.

Serious or Rare Side Effects: - Hyperkalemia: dangerously high potassium levels. - Acute kidney injury: sudden decline in renal function. - Angioedema: swelling of face, lips, tongue, or throat. - Severe hypotension: marked drop in blood pressure. - Liver enzyme elevation: significant rise in hepatic transaminases.

Before initiating Irbesartan, consider the following safety measures.

- Renal function: monitor serum creatinine and eGFR regularly. - Electrolytes: check potassium levels, especially if combined with potassium‑sparing agents. - Volume status: avoid use in patients who are volume‑depleted or on high‑dose diuretics. - Concomitant drugs: review for potential interactions with NSAIDs, lithium, or other RAAS inhibitors. - Pregnancy: contraindicated in pregnancy (Category D) due to risk of fetal toxicity. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with several medicines, requiring clinical attention.

Major Interactions (Avoid): - Dual RAAS blockade (e.g., ACE inhibitors, aliskiren): increased risk of renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics or supplements: can cause severe hyperkalemia. - Lithium: may raise lithium concentrations, leading to toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive effect and impair renal function. - Cyclosporine: can increase serum Irbesartan levels. - Rifampin: may lower Irbesartan concentrations, reducing efficacy.